(Q44813441)

English

Phase I and pharmacokinetic study of a low-clearance, unilamellar liposomal formulation of lurtotecan, a topoisomerase 1 inhibitor, in patients with advanced leukemia

scientific article published in April 2004

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

Phase I and pharmacokinetic study of a low-clearance, unilamellar liposomal formulation of lurtotecan, a topoisomerase 1 inhibitor, in patients with advanced leukemia (English)

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

1 reference

based on heuristic

inferred from title

pharmacokinetics

1 reference

based on heuristic

inferred from title

Hagop Kantarjian

11

object named as

Hagop M Kantarjian

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

Srdan Verstovsek

7

object named as

Srdan Verstovsek

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

William G Wierda

6

object named as

William G Wierda

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

Guillermo Garcia-Manero

3

object named as

Guillermo Garcia-Manero

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

Jorge Eduardo Cortes

4

object named as

Jorge E Cortes

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

10

object named as

Maher Albitar

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

Martin S. Tallman

2

object named as

Martin S Tallman

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

Francis J Giles

1

object named as

Francis J Giles

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

author name string

Deborah A Thomas

5

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

Marta Hamilton

8

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

Emma Barrett

9

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

language of work or name

0 references

publication date

1 April 2004

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

100

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

7

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

1449-1458

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

Results of topotecan single-agent therapy in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20132

21 January 2018

Activity of oral and intravenous 9-aminocamptothecin in SCID mice engrafted with human leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20132

21 January 2018

Phase I and pharmacological study of the new topoisomerase I inhibitor GI147211, using a daily x 5 intravenous administration

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20132

21 January 2018

A phase I clinical and pharmacokinetic study of the new topoisomerase inhibitor GI147211 given as a 72-h continuous infusion

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20132

21 January 2018

Effective irinotecan (CPT-11)-containing liposomes: intraliposomal conversion to the active metabolite SN-38.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20132

21 January 2018

Modulation of doxorubicin resistance in a doxorubicin-resistant human leukaemia cell by an immunoliposome targeting transferring receptor

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20132

21 January 2018

Acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20132

21 January 2018

Topotecan and cytarabine is an active combination regimen in myelodysplastic syndromes and chronic myelomonocytic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20132

7 January 2021

based on heuristic

inferred from DOI database lookup

Cyclophosphamide, ara-C and topotecan (CAT) for patients with refractory or relapsed acute leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20132

7 January 2021

based on heuristic

inferred from DOI database lookup

Mylotarg combined with topotecan and cytarabine in patients with refractory acute myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20132

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I and pharmacologic study of 9-aminocamptothecin colloidal dispersion formulation in patients with refractory or relapsed acute leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20132

7 January 2021

based on heuristic

inferred from DOI database lookup

Water soluble inhibitors of topoisomerase I: quaternary salt derivatives of camptothecin

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20132

7 January 2021

based on heuristic

inferred from DOI database lookup

Synthesis and antitumor activity of novel water soluble derivatives of camptothecin as specific inhibitors of topoisomerase I

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20132

7 January 2021

based on heuristic

inferred from DOI database lookup

Liposomal lurtotecan (NX211): determination of total drug levels in human plasma and urine by reversed-phase high-performance liquid chromatography.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20132

7 January 2021

based on heuristic

inferred from DOI database lookup

OSI-211, a novel liposomal topoisomerase I inhibitor, is active in SCID mouse models of human AML and ALL.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20132

7 January 2021

based on heuristic

inferred from DOI database lookup

Determination of camptothecin analogs in biological matrices by high-performance liquid chromatography

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20132

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I study of liposomal daunorubicin in patients with acute leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20132

7 January 2021

based on heuristic

inferred from DOI database lookup

High-dose liposomal daunorubicin and high-dose cytarabine combination in patients with refractory or relapsed acute myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20132

7 January 2021

based on heuristic

inferred from DOI database lookup

Population pharmacokinetic and dynamic analysis of the topoisomerase I inhibitor lurtotecan in phase II studies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20132

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical pharmacokinetics of camptothecin topoisomerase I inhibitors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20132

7 January 2021

based on heuristic

inferred from DOI database lookup

Modulation of camptothecin analogs in the treatment of cancer: a review

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20132

7 January 2021

based on heuristic

inferred from DOI database lookup

Activity and toxicity of GI147211 in breast, colorectal and non-small-cell lung cancer patients: an EORTC-ECSG phase II clinical study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20132

7 January 2021

based on heuristic

inferred from DOI database lookup

Second-line treatment of small-cell lung cancer with the camptothecin-derivative GI147211: a study of the EORTC Early Clinical Studies Group (ECSG).

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20132

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I/pharmacokinetic study of the topoisomerase I inhibitor GG211 administered as a 21-day continuous infusion.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20132

7 January 2021

based on heuristic

inferred from DOI database lookup

Stabilization of topotecan in low pH liposomes composed of distearoylphosphatidylcholine

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20132

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of liposomalization on the antitumor activity, side-effects and tissue distribution of CPT-11

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20132

7 January 2021

based on heuristic

inferred from DOI database lookup

Liposomal daunorubicin (DaunoXome) for treatment of poor-risk acute leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20132

7 January 2021

based on heuristic

inferred from DOI database lookup

Liposomal vincristine in relapsed non-Hodgkin's lymphomas: early results of an ongoing phase II trial.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20132

7 January 2021

based on heuristic

inferred from DOI database lookup

Intratumor distribution of doxorubicin following i.v. administration of drug encapsulated in egg phosphatidylcholine/cholesterol liposomes

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20132

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.20132

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44813441&oldid=2143685466"